|
|
| (31 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{pnc}} | + | {{gohome}} |
| | + | {{ft|P}} |
| | + | '''CHERRYPICKING STUDIES IS NOT SCIENCE |
| | + | {{qt|Reviews on covid drug development}} |
| | | | |
| − | current items will be put into the subsections.
| |
| | | | |
| − | *[[reviews on covid drug development]] | + | *'''[[scouting ideas]]''' |
| − | *[[scouting ideas]]
| + | |
| | | | |
| − | *[[Patients on biologicals]] | + | *'''[[PHA Biologicals]]''' |
| − | *[[HMGB1, RAGE]]
| + | |
| − | *[[pre-Interleukin 6]]
| + | |
| − | *[[post-Interleukin 6]]
| + | |
| − | *[[pre-TNFalpha]]
| + | |
| − | *[[post-TNFalpha]]
| + | |
| − | *[[pre-Interleukin 17]]
| + | |
| − | *[[post-Interleukin 17]]
| + | |
| − | *[[pre-Interleukin 1]]
| + | |
| − | *[[post-Interleukin 1]]
| + | |
| − | *[[Inflammasome]] ''colchicine''
| + | |
| − | *[[Methotrexate]]
| + | |
| − | *[[other anti-inflammatory]]
| + | |
| − | *[[NK-kappaB]]
| + | |
| − | *[[STAT 3]]
| + | |
| − | *[[JAK Janus Kinase]]
| + | |
| − | *[[Corticosteroids]]
| + | |
| − | *[[Cytokine absorbers]]
| + | |
| − | *[[Target Complement system]]
| + | |
| − | *[[Target Extracellular traps]]
| + | |
| − | *[[TGF beta]]
| + | |
| − | *[[Anticoagulant in covid19]]
| + | |
| − | *[[Antioxidants]]
| + | |
| − | *[[Stem cells]]
| + | |
| − | *[[MDSC cells]]
| + | |
| − | *[[Interferons]]
| + | |
| | | | |
| | + | *'''[[PHA conventional pharmacology]]''' |
| | | | |
| − | *[[other single compounds]] | + | *'''[[PHA retargeted compounds]]''' |
| − | *[[Retargeted single compounds]]
| + | |
| − | *[[Hydroxychloroquine]]
| + | |
| − | *
| + | |
| − | *[[Target ACE2, Spike protein]]
| + | |
| − | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
| + | |
| − | *[[other antiviral compounds]]
| + | |
| − | *[[AV Remdesivir]]
| + | |
| − | *[[AV Lopinavir]]
| + | |
| − | *[[AV Ivermectin]]
| + | |
| − | *[[AV Arabidol]]
| + | |
| − | *[[AV Favipiravir]]
| + | |
| | | | |
| | + | *'''[[PHA antivirals by mechanism]]''' |
| | | | |
| | + | *'''[[PHA pharmacophore by screened target]]''' |
| | | | |
| − | *[[Vitamin D]] | + | *'''[[PHA ImmunoNutrients]] |
| − | *[[Anorganic nutrients Magnesium]]
| + | |
| − | *[[Anorganic nutrients Selenium]]
| + | |
| − | *[[Anorganic nutrients Zinc]]
| + | |
| − | *[[Nutrition, general]]
| + | |
| − | *[[Exercise, Vibration]]
| + | |
| | | | |
| | + | *'''[[PHA compl altern natural]]''' |
| | | | |
| − | *[[Traditional Chinese Medicine]] | + | *'''[[PHA within indications compounds]]''' |
| − | *[[Natural compounds]]
| + | |
| | | | |
| − | *[[Statins]] | + | *'''[[PHA Serum products]]''' |
| − | *[[Antidiabetic compounds, any]]
| + | |
| − | *[[RSP - On RAS drugs]]
| + | |
| | | | |
| − | *[[Reconvalescent blood products, Passive vaccine]] | + | *'''[[PHA Vaccination]]''' |
| − | *[[Plasmapheresis]]
| + | |
| | + | PHA related options: |
| | | | |
| − | *[[Immunodeviation]] e.g. by adjuvants or other vaccinations
| |
| | *[[Radiation therapy]] | | *[[Radiation therapy]] |
| | *[[Phototherapy]] | | *[[Phototherapy]] |
| − | *[[Active vaccine]] | + | *[[Electric fields]] |
| | + | *[[Treatment other concepts]] |
| | + | |
| | + | |
| | + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| | + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| | + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| | + | Paper is (not yet in PubMed) : |
| | | | |
| − | ===-rest-===
| + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| − | {{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
| + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| − | {{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
| + | based on e.g. |
| − | {{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32358890|t=2020. Cutaneous side-effects of the potential COVID-19 drugs.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats |pdf=|usr=}}
| + | |
| − | {{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
| + | |
| − | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
| + | |
| − | {{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
| + | |
| − | {{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
| + | |
| − | {{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
| + | |
| − | {{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
| + | |
| − | {{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
| + | |
| − | {{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
| + | |
| − | {{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
| + | |
| | | | |
| − | ===009=== | + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| | | | |
| | + | ======================================================================================= |
| | | | |
| − | {{tp|p=32535032|t=2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.|pdf=|usr=009}}
| + | COVID19 is now a CURABLE disease !!! |
| − | {{tp|p=32435607|t=2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32423449|t=2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32493510|t=2020. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32405423|t=2020. Minimum costs to manufacture new treatments for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32405422|t=2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32405421|t=2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32401274|t=2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32392282|t=2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32501511|t=2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32530438|t=2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32459647|t=2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32384188|t=2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32533592|t=2020. Pharmacist's perspective on HCQ treatment of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32460458|t=2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32401715|t=2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32401712|t=2020. Interferon beta-1b for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32410758|t=2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450109|t=2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473680|t=2020. The starting line for COVID-19 vaccine development.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450106|t=2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445630|t=2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450054|t=2020. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473139|t=2020. Death threats after a trial on chloroquine for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32518920|t=2020. Caution and clarity required in the use of chloroquine for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32501454|t=2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32535078|t=2020. Vaccination strategies to combat novel corona virus SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32535080|t=2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32497632|t=2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454157|t=2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450171|t=2020. Coronaviruses pandemics: Can neutralizing antibodies help?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450166|t=2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32422305|t=2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32418894|t=2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32478465|t=2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425245|t=2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32416415|t=2020. Etoposide-based therapy for severe forms of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32504923|t=2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32498007|t=2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32492562|t=2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32480250|t=2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464491|t=2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473509|t=2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32470789|t=2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32534175|t=2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464494|t=2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526507|t=2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464492|t=2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425307|t=2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425306|t=2020. Protective potential of Expectorants against COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425303|t=2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32428811|t=2020. Exercise as medicine for COVID-19: An ACE in the hole?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32416408|t=2020. As a potential treatment of COVID-19: Montelukast.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32413699|t=2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531538|t=2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531537|t=2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32516733|t=2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32535456|t=2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32534337|t=2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32505075|t=2020. Fighting against frailty and sarcopenia - As well as COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32505072|t=2020. COVID-19 and picotechnology: Potential opportunities.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32505069|t=2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32400020|t=2020. COVID-19 and implications for thiopurine use.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32470350|t=2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473390|t=2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32437926|t=2020. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445881|t=2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32442649|t=2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32533920|t=2020. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445440|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445439|t=2020. Surgery Scheduling in a Crisis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32433465|t=2020. Immunogenicity of a DNA vaccine candidate for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32529545|t=2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32499636|t=2020. COVID-19 vaccines: neutralizing antibodies and the alum advantage.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32533109|t=2020. Passive antibody therapy in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32393823|t=2020. BCG-induced trained immunity: can it offer protection against COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32462282|t=2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32451597|t=2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32430617|t=2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32350818|t=2020. Chloroquine-induced QTc prolongation in COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32342609|t=2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32383751|t=2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528732|t=2020. Universal coronavirus vaccines: the time to start is now.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32509338|t=2020. Certainty of success: three critical parameters in coronavirus vaccine development.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32521760|t=2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532069|t=2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528623|t=2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32456404|t=2020. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454586|t=2020. Demand for potentially hazardous COVID-19 treatments.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454583|t=2020. ICER releases pricing models for potential COVID-19 treatments.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473310|t=2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445956|t=2020. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
| + | |
| − | {{tp|p=32442720|t=2020. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32430286|t=2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?|pdf=|usr=009}}
| + | |
| | | | |
| − | {{tp|p=32405226|t=2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.|pdf=|usr=009}}
| + | ======================================================================================= |
| − | {{tp|p=32438037|t=2020. Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32438034|t=2020. Does lopinavir really inhibit SARS-CoV-2?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32407959|t=2020. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32502640|t=2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32437972|t=2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425361|t=2020. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32493609|t=2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32519302|t=2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32415971|t=2020. Use of statins in patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32415962|t=2020. Reply: Use of statins in patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32437821|t=2020. Radiation therapy for COVID-19 pneumopathy.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32437820|t=2020. Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32413531|t=2020. Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32522574|t=2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32514354|t=2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32394513|t=2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32426001|t=2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32395001|t=2020. Evidencia viva como respuesta a las controversias en el uso de antimalaricos en COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32414660|t=2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32491104|t=2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32501367|t=2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32418114|t=2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32518317|t=2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32413619|t=2020. beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32513867|t=2020. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32434945|t=2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32404477|t=2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32385228|t=2020. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32467561|t=2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32460839|t=2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526079|t=2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32388805|t=2020. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32394099|t=2020. Low-dose radiotherapy for SARS-CoV-2 pneumonia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32412544|t=2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528195|t=2020. Broad beans (Vicia faba) and the potential to protect from COVID-19 coronavirus infection.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528194|t=2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32436460|t=2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32436445|t=2020. Potential specific therapies in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32483428|t=2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473812|t=2020. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32418732|t=2020. Chloroquine and hydroxychloroquine during pregnancy: What do we know?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32457932|t=2020. Chloroquine, hydroxychloroquine and COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32487513|t=2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532691|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32467007|t=2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425645|t=2020. Use of convalescent plasma in COVID-19 patients in China.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32406985|t=2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473994|t=2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32485391|t=2020. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32360423|t=2020. Malaria prophylaxis approach during COVID-19 pandemic.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32471655|t=2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454984|t=2020. Battling COVID-19: using old weapons for a new enemy.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32387011|t=2020. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32418794|t=2020. A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526960|t=2020. Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531955|t=2020. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32236815|t=2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32524253|t=2020. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32530808|t=2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531236|t=2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532094|t=2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532085|t=2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32417996|t=2020. BCG versus COVID-19: impact on urology.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
| + | |
